Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described pre...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Breast Cancer Res Treat
Главные авторы: Cortes, Javier, Hudgens, Stacie, Twelves, Chris, Perez, Edith A., Awada, Ahmad, Yelle, Louise, McCutcheon, Susan, Kaufman, Peter A., Forsythe, Anna, Velikova, Galina
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2015
Предметы:
Clinical Trial
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661183/
https://ncbi.nlm.nih.gov/pubmed/26567010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3633-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы